AXL in cancer: a modulator of drug resistance and therapeutic target

被引：34

作者：

Tang, Yaoxiang ^{[1
]}

Zang, Hongjing ^{[1
]}

Wen, Qiuyuan ^{[1
]}

Fan, Songqing ^{[1
]}

机构：

[1] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China

来源：

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2023年 / 42卷 / 01期

基金：

中国国家自然科学基金;

关键词：

AXL; Cancer; Drug resistance; Target therapy; Molecular mechanisms; RECEPTOR TYROSINE KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; BREAST-CANCER; DNA-DAMAGE; GAS6/AXL AXIS; EGFR-TKI; INHIBITION; PROMOTES;

D O I：

10.1186/s13046-023-02726-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance. Recent studies revealed that reducing AXL expression can weaken cancer cells' drug resistance, indicating that AXL may be a promising target for anti-cancer drug treatment. This review aims to summarize the AXL's structure, the mechanisms regulating and activating it, and its expression pattern, especially in drug-resistant cancers. Additionally, we will discuss the diverse functions of AXL in mediating cancer drug resistance and the potential of AXL inhibitors in cancer treatment.

引用

页数：14

共 50 条

[1] AXL in cancer: a modulator of drug resistance and therapeutic target
Yaoxiang Tang
Hongjing Zang
Qiuyuan Wen
Songqing Fan
Journal of Experimental & Clinical Cancer Research, 42
[2] Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
Li, Y.
Ye, X.
Tan, C.
Hongo, J-A
Zha, J.
Liu, J.
Kallop, D.
Ludlam, M. J. C.
Pei, L.
ONCOGENE, 2009, 28 (39) : 3442 - 3455
[3] Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
Y Li
X Ye
C Tan
J -A Hongo
J Zha
J Liu
D Kallop
M J C Ludlam
L Pei
Oncogene, 2009, 28 : 3442 - 3455
[4] Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance
Wang, Yumin
Chen, Yongming
Zhang, Junjing
Yang, Yihui
Fleishman, Joshua S.
Wang, Yan
Wang, Jinhua
Chen, Jichao
Li, Yuanfang
Wang, Hongquan
DRUG RESISTANCE UPDATES, 2024, 72
[5] AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Rankin, Erinn B.
Fuh, Katherine C.
Taylor, Tiffany E.
Krieg, Adam J.
Musser, Margaret
Yuan, Jenny
Wei, Kevin
Kuo, Calvin J.
Longacre, Teri A.
Giaccia, Amato J.
CANCER RESEARCH, 2010, 70 (19) : 7570 - 7579
[6] AXL is a potential target for therapeutic intervention in breast cancer progression
Zhang, Yi-Xiang
Knyazev, Peter G.
Cheburkin, Yuri V.
Sharma, Kirti
Knyazev, Yuri P.
Orfi, Laszlo
Szabadkai, Istvan
Daub, Henrik
Keri, Gyoergy
Ullrich, Axel
CANCER RESEARCH, 2008, 68 (06) : 1905 - 1915
[7] Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
Levin, Pavel A.
Brekken, Rolf A.
Byers, Lauren Averett
Heymach, John V.
Gerber, David E.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) : 1357 - 1362
[8] Does Axl have potential as a therapeutic target in pancreatic cancer?
Du, Wenting
Brekken, Rolf A.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (11) : 955 - 966
[9] The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance
Yao, Shang
Fan, Lavender Yuen-Nam
Lam, Eric Wing-Fai
SEMINARS IN CANCER BIOLOGY, 2018, 50 : 77 - 89
[10] MicroRNA-21: a therapeutic target for reversing drug resistance in cancer
Hong, Liu
Han, Yu
Zhang, Yujie
Zhang, Hongwei
Zhao, Qingchuan
Wu, Kaichun
Fan, Daiming
EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (09) : 1073 - 1080

← 1 2 3 4 5 →